The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-ResistantStaphylococcus aureusBacteriolysis | Zendy

Chiara Indiani | Zendy; Karen Sauve | Zendy; Assaf Raz | Zendy; Wessam Abdelhady | Zendy; Yan Q. Xiong | Zendy; Cara Cassino | Zendy; Arnold S. Bayer | Zendy; Raymond Schuch | Zendy

Open Access

The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-ResistantStaphylococcus aureusBacteriolysis

Author(s) -

Chiara Indiani,

Karen Sauve,

Assaf Raz,

Wessam Abdelhady,

Yan Q. Xiong,

Cara Cassino,

Arnold S. Bayer,

Raymond Schuch

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02291-18

Subject(s) - lysin , microbiology and biotechnology , staphylococcus aureus , bacteremia , antibiotics , staphylococcal infections , methicillin resistant staphylococcus aureus , antimicrobial , endocarditis , antibiotic resistance , bacteriophage , biology , medicine , bacteria , escherichia coli , biochemistry , genetics , gene

Bacteriophage-derived lysins are cell-wall-hydrolytic enzymes that represent a potential new class of antibacterial therapeutics in development to address burgeoning antimicrobial resistance. CF-301, the lead compound in this class, is in clinical development as an adjunctive treatment to potentially improve clinical cure rates ofStaphylococcus aureus bacteremia and infective endocarditis (IE) when used in addition to antibiotics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research